Trending News

Caught in the Act: Practical and Legal Considerations When Executives’ Office Love Affair Exposed

Florida’s CHOICE Act Becomes Law, Enhancing Certain Non-Compete Agreements

Labor Secretary Lifts Abeyance on OFCCP Disability and Veteran Matters

In Case You Missed It: DOL Prohibited From Collecting Liquidated Damages in Wage & Hour Pre-Litigation Investigations

SEC’s New Concept Release on Foreign Private Issuer Standards

What Regulated Businesses Should Know About the Supreme Court’s Recent NEPA Decision

NEW ATDS BATTLEGROUND: Texas Passes HUGE NEW AMENDMENT to Its State Telemarketing Law Reviving The Risk of Autodialer Cases

Supreme Court Eliminates Heightened Discrimination Standard Under Title VII

Cleaning the Cupboard—Six More Decisions in One Day, and a Largely Harmonious Court - SCOTUS Today

U.S. Supreme Court Holds Majority-Group Plaintiffs Are Not Subject to a Heightened Evidentiary Standard Under Title VII

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ASCO 2025
Posted On Saturday, May 31, 2025
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
Posted On Saturday, May 31, 2025
Celularity Receives Nasdaq Notice Regarding Form 10-Q
Posted On Friday, May 30, 2025
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders
Posted On Friday, May 30, 2025
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
Posted On Friday, May 30, 2025
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights
Posted On Friday, May 30, 2025
NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association
Posted On Friday, May 30, 2025
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
Posted On Friday, May 30, 2025
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
Posted On Friday, May 30, 2025
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
Posted On Friday, May 30, 2025
PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla
Posted On Friday, May 30, 2025
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
Posted On Friday, May 30, 2025
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
Posted On Friday, May 30, 2025
Syncromune® Announces First Patient Dosed in LEGION-100 Phase 2a Trial of SYNC-T® Therapy SV-102 for Patients with Metastatic Castration-Resistant Prostate Cancer
Posted On Friday, May 30, 2025
CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference
Posted On Friday, May 30, 2025
Shareholder Update
Posted On Friday, May 30, 2025
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
Posted On Friday, May 30, 2025
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
Posted On Friday, May 30, 2025
Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer
Posted On Friday, May 30, 2025
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
Posted On Friday, May 30, 2025
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
Posted On Friday, May 30, 2025
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
Posted On Friday, May 30, 2025
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
Posted On Friday, May 30, 2025
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
Posted On Friday, May 30, 2025
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
Posted On Friday, May 30, 2025

Print